Dirk Tomsitz

7PUBLICATIONS
12CO-AUTHORS
ChemotherapyCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Sep 04, 2025
Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial.

Sebastian Haferkamp, Bastian Schilling, Carola Berking

|Mar 22, 2025
Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.

Dirk Tomsitz, Elisabeth Livingstone, Carmen Loquai

|Jul 14, 2023
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study.

Dirk Tomsitz, Theresa Ruf, Markus Heppt

|May 13, 2023
Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors.

Dirk Tomsitz, Theresa Ruf, Sarah Zierold

|Jul 09, 2022
Development of Lymphopenia during Therapy with Immune Checkpoint Inhibitors Is Associated with Poor Outcome in Metastatic Cutaneous Melanoma.

Dirk Tomsitz, Max Schlaak, Sarah Zierold

|Aug 21, 2021
Successful treatment of disseminated superficial actinic porokeratosis with topical 2% cholesterol/ 2% lovastatin cream: a case series with 7 patients.

D Tomsitz, T Biedermann

Pageof 2

Frequent Collaborators

3 joint publications

Bastian Schilling

1 joint publications

Knut Brockow

1 joint publications

Markus Heppt

1 joint publications

Ramon Staeger